Clinical trial · people
Cerebrolysin after thrombectomy: 68% vs 44% independent at 90 days
Checked against the paper Clinical trialPublished by PepVault
The takeaway
This study adds an early, non-randomized signal of better 90-day recovery with Cerebrolysin after thrombectomy in a selected stroke group, which still needs confirmation in randomized trials.
- Kind
- Clinical trial
- Studied in
- People
- Published
- 2025
- Journal
- Transl Stroke Res
What they tested
The team tested whether adding Cerebrolysin to mechanical thrombectomy (removing a brain clot with a device) improves recovery and safety after a major ischemic stroke.
How the study was done
An open-label, single-arm study at one center of 50 consecutive adults with moderate-to-severe ischemic stroke from a large artery blockage, all treated with thrombectomy within 6 h of onset, with outcomes scored by assessors who were blinded. Patients got Cerebrolysin 30 ml by IV through day 21, then a second cycle between days 69 and 90, and were compared with 50 past patients matched by propensity scores (a statistical matching method).

What they found
At 90 days, 68% of the Cerebrolysin group were functionally independent (mRS 0-2, a disability score) versus 44% of controls (OR 2.7, 95% CI 1.2-6.1). Secondary brain bleeding was less common, at 14% versus 40% (RR 0.37), and the median NIHSS stroke severity score on day 7 was 3 versus 6. Barthel Index scores, a measure of daily-living ability, were higher at 30 days (median 77 vs 63) and at 3 months (86 vs 75), mostly from mobility and transfer items. Deaths were similar between groups, at 2% vs 6% at 30 days and 8% vs 12% at 90 days.
What it doesn’t show
This was not a randomized trial: everyone knew they were getting Cerebrolysin, the comparison group came from earlier patients, and it ran at one center for 3 months. It only included selected patients with good collateral blood flow and successful clot removal, and the authors call for randomized trials to confirm the results.
The paper
Staszewski et al. Efficacy of Cerebrolysin Treatment as an Add-On Therapy to Mechanical Thrombectomy in Patients with Acute Ischemic Stroke Due to Large Vessel Occlusion in Anterior Circulation: Results of a 3-Month Follow-up of a Prospective, Open Label, Single-Center Study. Transl Stroke Res. 2025.
The compound
More studies on Cerebrolysin
- Cerebrolysin: small cognitive gain in vascular dementia, weak evidenceMeta-analysis · people · 2019
- Cerebrolysin: better NIHSS scores after stroke across nine trialsMeta-analysis · people · 2018
- Cerebrolysin beat placebo on global change in Alzheimer's at 6 monthsMeta-analysis · people · 2015
- Cerebrolysin: better arm function at day 90 after stroke in CARSRandomized trial · people · 2016
- Cerebrolysin: no overall benefit in acute ischemic stroke at 90 daysRandomized trial · people · 2012
- Every study on Cerebrolysin
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.